SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis

por Njouendou, Abdel Jelil, Szarvas, Tibor, Tiofack, Arnol Auvaker Zebaze, Kenfack, Rovaldo Nguims, Tonouo, Pamela Derliche, Ananga, Sidonie Noa, Bell, Esther H. M. Dina, Simo, Gustave, Hoheisel, Jörg D., Siveke, Jens T., Lueong, Smiths S.
Publicado 2023